Sentiment-Signal
10,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (18.02.2026)
HOCH Abgang Schlüsselpersonen (18.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 18.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of directors or certain officers; election of directors; appoi |
| 17.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers On January 15, 2025, Rosemary |
| 05.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☒ Item 5.02 Departure of directors or certain officers; election of directors; appo |
| 18.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☒ Item 5.02 Departure of directors or certain officers; election of directors; appointm |
Stammdaten
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Unternehmen & Branche
| Name | Tarsus Pharmaceuticals, Inc. |
|---|---|
| Ticker | TARS |
| CIK | 0001819790 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,58 Mrd. USD |
| Beta | 0,63 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 451,360,000 | -66,418,000 | -1.59 | 562,158,000 | 343,426,000 |
| 2025-09-30 | 10-Q | 118,697,000 | -12,585,000 | -0.30 | 534,561,000 | 335,082,000 |
| 2025-06-30 | 10-Q | 102,660,000 | -20,340,000 | -0.48 | 494,994,000 | 332,612,000 |
| 2025-03-31 | 10-Q | 78,335,000 | -25,120,000 | -0.64 | 500,750,000 | 342,458,000 |
| 2024-12-31 | 10-K | 182,953,000 | -115,554,000 | -3.07 | 376,991,000 | 224,534,000 |
| 2024-09-30 | 10-Q | 48,118,000 | -23,420,000 | -0.61 | 376,300,000 | 237,484,000 |
| 2024-06-30 | 10-Q | 40,813,000 | -33,290,000 | -0.88 | 376,844,000 | 252,246,000 |
| 2024-03-31 | 10-Q | 27,614,000 | -35,731,000 | -1.01 | 349,278,000 | 275,211,000 |
| 2023-12-31 | 10-K | 17,447,000 | -135,893,000 | -4.62 | 265,491,000 | 196,988,000 |
| 2023-09-30 | 10-Q | 1,871,000 | -39,148,000 | -1.28 | 268,332,000 | 213,664,000 |
| 2023-06-30 | 10-Q | 0 | -31,424,000 | -1.17 | 188,927,000 | 147,729,000 |
| 2023-03-31 | 10-Q | 2,500,000 | -23,419,000 | -0.88 | 211,214,000 | 173,404,000 |
| 2022-12-31 | 10-K | 25,816,000 | -62,091,000 | -2.52 | 227,863,000 | 192,900,000 |
| 2022-09-30 | 10-Q | 0 | -22,511,000 | -0.84 | 236,465,000 | 202,627,000 |
| 2022-06-30 | 10-Q | 15,277,000 | -5,743,000 | -0.24 | 252,828,000 | 221,505,000 |
| 2022-03-31 | 10-Q | 539,000 | -20,238,000 | -0.98 | 181,483,000 | 149,197,000 |
| 2021-12-31 | 10-K | 57,027,000 | -13,827,000 | -0.67 | 178,907,000 | 166,730,000 |
| 2021-09-30 | 10-Q | 1,240,000 | -15,697,000 | -0.76 | 190,412,000 | 179,142,000 |
| 2021-06-30 | 10-Q | 22,017,000 | 6,345,000 | 0.29 | 203,450,000 | 192,471,000 |
| 2021-03-31 | 10-Q | 33,432,000 | 10,376,000 | 0.47 | 193,954,000 | 183,232,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-19 | Azamian Bobak R. | Director, Officer, President/CEO and Board Chair | Open Market Sale | -11,964 | 67.00 | -801,588.00 | -225,4% | |
| 2026-03-19 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -4,174 | 67.00 | -279,658.00 | -78,6% | |
| 2026-03-19 | Wahl Bryan | Officer, General Counsel | Open Market Sale | -4,231 | 67.00 | -283,477.00 | -79,7% | |
| 2026-03-19 | Mottiwala Aziz | Officer, Chief Commercial Officer | Open Market Sale | -4,440 | 67.00 | -297,480.00 | -83,7% | |
| 2026-03-19 | Farrow Jeffrey S | Officer, See Remarks | Open Market Sale | -2,186 | 67.00 | -146,462.00 | -41,2% | |
| 2026-03-19 | Lin Elizabeth Yeu | Officer, Chief Medical Officer | Open Market Sale | -390 | 67.00 | -26,130.00 | -7,3% | |
| 2026-03-19 | Neervannan Seshadri | Officer, Chief Operating Officer | Open Market Sale | -4,589 | 67.00 | -307,463.00 | -86,5% | |
| 2026-03-18 | Azamian Bobak R. | Director, Officer, President/CEO and Board Chair | Open Market Sale | -11,667 | 68.71 | -801,639.57 | -225,4% | |
| 2026-03-18 | Wahl Bryan | Officer, General Counsel | Open Market Sale | -4,125 | 68.71 | -283,428.75 | -79,7% | |
| 2026-03-18 | Lin Elizabeth Yeu | Officer, Chief Medical Officer | Open Market Sale | -379 | 68.71 | -26,041.09 | -7,3% | |
| 2026-03-18 | Mottiwala Aziz | Officer, Chief Commercial Officer | Open Market Sale | -4,330 | 68.71 | -297,514.30 | -83,7% | |
| 2026-03-18 | Farrow Jeffrey S | Officer, See Remarks | Open Market Sale | -2,133 | 68.71 | -146,558.43 | -41,2% | |
| 2026-03-18 | Neervannan Seshadri | Officer, Chief Operating Officer | Open Market Sale | -3,610 | 68.71 | -248,043.10 | -69,8% | |
| 2026-03-18 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -4,071 | 68.71 | -279,718.41 | -78,7% | |
| 2026-03-17 | Farrow Jeffrey S | Officer, See Remarks | Open Market Sale | -2,111 | 69.42 | -146,545.62 | -41,2% | |
| 2026-03-17 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -4,029 | 69.42 | -279,693.18 | -78,7% | |
| 2026-03-17 | Wahl Bryan | Officer, General Counsel | Open Market Sale | -4,084 | 69.42 | -283,511.28 | -79,7% | |
| 2026-03-17 | Neervannan Seshadri | Officer, Chief Operating Officer | Open Market Sale | -3,125 | 69.42 | -216,937.50 | -61,0% | |
| 2026-03-17 | Azamian Bobak R. | Director, Officer, President/CEO and Board Chair | Open Market Sale | -10,972 | 69.42 | -761,676.24 | -214,2% | |
| 2026-03-17 | Mottiwala Aziz | Officer, Chief Commercial Officer | Open Market Sale | -4,286 | 69.42 | -297,534.12 | -83,7% | |
| 2026-03-17 | Lin Elizabeth Yeu | Officer, Chief Medical Officer | Open Market Sale | -375 | 69.42 | -26,032.50 | -7,3% | |
| 2026-03-16 | LINK WILLIAM J PHD | Director | Open Market Sale | -8,378 | 69.03 | -578,333.34 | -162,6% | |
| 2026-03-16 | LINK WILLIAM J PHD | Director | Open Market Sale | -493 | 69.75 | -34,386.75 | -9,7% | |
| 2026-03-16 | LINK WILLIAM J PHD | Director | Open Market Sale | -3,629 | 68.09 | -247,098.61 | -69,5% | |
| 2026-03-04 | Neervannan Seshadri | Officer, Chief Operating Officer | Open Market Sale | -8,366 | 76.67 | -641,421.22 | -180,4% | |
| 2026-01-02 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -8,122 | 80.71 | -655,526.62 | -184,3% | |
| 2026-01-02 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -5,715 | 80.09 | -457,714.35 | -128,7% | |
| 2026-01-02 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -893 | 82.93 | -74,056.49 | -20,8% | |
| 2026-01-02 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -835 | 81.90 | -68,386.50 | -19,2% | |
| 2025-12-24 | Azamian Bobak R. | Director, Officer, President/CEO and Board Chair | Open Market Sale | -557 | 83.54 | -46,531.78 | -13,1% | |
| 2025-12-24 | Azamian Bobak R. | Director, Officer, President/CEO and Board Chair | Open Market Sale | -5,443 | 82.41 | -448,557.63 | -126,1% | |
| 2025-12-16 | Lin Elizabeth Yeu | Officer, Chief Medical Officer | Open Market Sale | -2,078 | 79.50 | -165,201.00 | -46,5% | |
| 2025-12-16 | Whitfield Dianne C. | Officer, Chief Human Resources Officer | Open Market Sale | -7,397 | 80.10 | -592,499.70 | -166,6% | |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Open Market Sale | -6,306 | 81.75 | -515,515.50 | -145,0% | |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Open Market Sale | -5,680 | 80.71 | -458,432.80 | -128,9% | |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Open Market Sale | -5,046 | 80.80 | -407,716.80 | -114,7% | |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Open Market Sale | -4,766 | 81.50 | -388,429.00 | -109,2% | |
| 2025-12-15 | LINK WILLIAM J PHD | Director | Open Market Sale | -1,148 | 82.39 | -94,583.72 | -26,6% | |
| 2025-09-24 | Azamian Bobak R. | Director, Officer, President/CEO and Board Chair | Open Market Sale | -6,000 | 55.37 | -332,220.00 | -93,4% | |
| 2025-09-08 | LINK WILLIAM J PHD | Director | Open Market Sale | -27,116 | 57.00 | -1,545,612.00 | -434,6% | |
| 2025-08-11 | Azamian Bobak R. | Director, Officer, President/CEO and Board Chair | Open Market Sale | -6,000 | 50.00 | -300,000.00 | -84,4% | |
| 2025-06-17 | Farrow Jeffrey S | Officer, See Remarks | Open Market Sale | -13,608 | 40.42 | -550,035.36 | -154,7% | |
| 2025-06-16 | Lin Elizabeth Yeu | Officer, Chief Medical Officer | Open Market Sale | -1,006 | 41.08 | -41,326.48 | -11,6% | |
| 2025-06-09 | Mottiwala Aziz | Officer, Chief Commercial Officer | Open Market Sale | -17,500 | 43.76 | -765,800.00 | -215,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.